Rubicon Research Ltd.

NSE: RUBICON | BSE: 544578 | ASM

Expensive Star

Download real time

1608.50 -22.40 (-1.37%)

175.7K NSE+BSE Volume

NSE 05 Oct, 2026 3:50 PM (IST)

26,625.8

Market Cap

High in industry

Beta 1Year

Rubicon Research Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for RUBICON, BSE:544578 Rubicon Research Ltd.

Search Inside the pdf :

Rubicon Research Ltd.

15 Aug 2026

1608.50

-1.37%

Four straight post-IPO beats; execution remains stellar

Buy: Rubicon Research Ltd.

Target

Motilal Oswal

Rubicon Research (RUBICON) delivered its fourth consecutive earnings surprise since its IPO (4%/13%/16% beat on revenue/EBITDA/PAT)—a strong pattern of promise vs consistent superior execution.

Rubicon Research has gained 231.65% in the last 1 Year

Rubicon Research Ltd.

15 Aug 2026

1608.50

-1.37%

Four straight post-IPO beats; execution remains stellar

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (RUBICON) delivered its fourth consecutive earnings surprise since its IPO (4%/13%/16% beat on revenue/EBITDA/PAT)—a strong pattern of promise vs consistent superior execution.

Rubicon Research has gained 23.07% in the last 3 Months

Rubicon Research Ltd.

15 Aug 2026

1608.50

-1.37%

Four straight post-IPO beats; execution remains stellar

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (RUBICON) delivered its fourth consecutive earnings surprise since its IPO (4%/13%/16% beat on revenue/EBITDA/PAT)—a strong pattern of promise vs consistent superior execution.

Rubicon Research Ltd. is trading above its 200 day SMA of 1120.0

Rubicon Research Ltd.

14 Aug 2026

1608.50

-1.37%

Four straight post-IPO beats; execution remains stellar

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (RUBICON) delivered its fourth consecutive earnings surprise since its IPO (4%/13%/16% beat on revenue/EBITDA/PAT)—a strong pattern of promise vs consistent superior execution.

Rubicon Research has gained 23.07% in the last 3 Months

Rubicon Research Ltd.

30 May 2026

1608.50

-1.37%

Another quarter, another beat: The compounder delivers

Buy: Rubicon Research Ltd.

Target

Motilal Oswal

Rubicon Research (Rubicon) delivered another outstanding quarter, beating revenue, EBITDA, and PAT estimates by 4%, 11%, and 15%, respectively.

Rubicon Research has gained 107.59% in the last 6 Months

Rubicon Research Ltd.

15 Apr 2026

1608.50

-1.37%

Arinna acquisition: Unlocking distribution moat and domestic growth engine

Buy: Rubicon Research Ltd.

Target

Motilal Oswal

Rubicon Research (Rubicon) aims to make inroads into the central nervous system (CNS) therapy in India’s branded market (DF) through Arinna Lifescience (Arinna).